


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



wherein:

Cy is a group of Formula (2):



C₃₋₇cycloalkyl or phenyl;

R₁, R₂, R₃, R₄ and R₅ are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R₁, R₂, R₃, R₄ and R₅ is halogen, trifluoromethyl or nitrile;

R₆ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, amino or hydroxy;

R₇ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, optionally substituted amino or hydroxy;

R₈ is hydrogen, methyl or ethyl;

R₉ is optionally substituted straight-chained or branched C₁₋₆alkyl, optionally substituted straight-chained or branched C₂₋₆alkenyl, optionally substituted straight-chained or branched C₂₋₆alkynyl, C₃₋₇cycloalkyl or optionally substituted phenyl;


R₂₀ is hydrogen or straight-chained or branched C₁₋₃alkyl or R₉ and R₂₀ may together form C₃₋₇cycloalkyl;

R₁₀ is hydrogen or straight-chained or branched C₁₋₃alkyl;

R₁₁ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, -CO-N(R₁₄)R₁₅, carboxyl;

R₁₂ is hydroxy or -OR₁₆;

R₁₃ is hydrogen, straight-chained or branched C₁₋₆alkyl, straight-chained or branched C₂₋₆alkenyl, straight-chained or branched C₂₋₆alkynyl or a group of Formula (3):



R₁₄ and R₁₅, which may be the same or different, are hydrogen, optionally substituted straight-chained or branched C₁₋₄alkyl, C₃₋₇cycloalkyl, straight-chained or branched C₁₋₄alkyloxy, straight-chained or branched C₁₋₄alkylsulfonyl or a heterocyclic ring;

R₁₆ is straight-chained C₁₋₄alkyl;

R₁₇ is hydrogen or methyl;

R₁₈ and R₁₉ together form cycloalkyl or C₃₋₇cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

or a hydrate or pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2); or a hydrate or pharmaceutically acceptable salt thereof.

3. (Original) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1 , R_2 , R_3 , R_4 and R_5 is halogen and the others are hydrogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

4. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen or R_2 and R_3 are the same kind of halogen;
or a hydrate or pharmaceutically acceptable salt thereof.

5. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen and R_1 , R_2 , R_4 and R_5 are hydrogen, or R_2 and R_3 are the same kind of halogen and R_1 , R_4 and R_5 are hydrogen;
or a hydrate or pharmaceutically acceptable salt thereof.

6. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1 , R_2 , R_3 , R_4 and R_5 is trifluoromethyl and the others are hydrogen, halogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

7. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1 , R_2 , R_3 , R_4 and R_5 is nitrile and the others are hydrogen, halogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

8. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is trifluoromethyl;
or a hydrate or pharmaceutically acceptable salt thereof.

9. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R₃ is nitrile;
or a hydrate or pharmaceutically acceptable salt thereof.

Claims 10-12. (Canceled)

13. (Previously Presented) The compound according to claim 1, wherein R₆ in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

14. (Previously Presented) The compound according to claim 1, wherein R₇ in Formula (1) is hydrogen or optionally substituted amino; or a hydrate or pharmaceutically acceptable salt thereof.

15. (Previously Presented) The compound according to claim 1, wherein R₈ in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

16. (Previously Presented) The compound according to claim 1, wherein R₉ in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl;
or a hydrate or pharmaceutically acceptable salt thereof.

17. (Previously Presented) The compound according to claim 1, wherein R₂₀ in Formula (1) is hydrogen or methyl;
or a hydrate or pharmaceutically acceptable salt thereof.

18. (Previously Presented) The compound according to claim 1, wherein R_{10} in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

19. (Previously Presented) The compound according to claim 1, wherein R_{11} in Formula (1) is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,; or a hydrate or pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound according to claim 1, wherein R_{12} in Formula (1) is hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

21. (Previously Presented) The compound according to claim 1, wherein R_{13} in Formula (1) is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl; or a hydrate or pharmaceutically acceptable salt thereof.

22. (Previously Presented) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of R_1 , R_2 , R_3 , R_4 and R_5 is halogen and the others are hydrogen or hydroxy;
 R_6 is hydrogen or methyl;
 R_7 is hydrogen or optionally substituted amino;
 R_8 is hydrogen or methyl;

R₉ is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;

R₂₀ is hydrogen;

R₁₀ is hydrogen or methyl;

R₁₁ is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tert-butylcarbamoyl, , methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl,;

R₁₂ is hydroxy;

R₁₃ is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;

or a hydrate or pharmaceutically acceptable salt thereof.

23. (Original) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(3,4-F₂)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenyl)propanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-

amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidomethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Et-


Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂SO₂CH₃, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHET, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHET, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHET, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHET, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHET, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHET, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHlPr;
or a hydrate or pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Previously Presented) A compound of Formula (4):




wherein

Cy, R₆, R₈, R₉, R₂₀, R₁₀, R₁₂, R₁₃, X and Y are as defined in claim 1;

R₇' is hydrogen, straight-chained or branched C₁₋₃alkyl optionally having at least one protected substituent, amino optionally having at least one protected substituent or protected hydroxy; and

R₁₁" is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, -CO-N(R₁₄)R₁₅, wherein R₁₄ and R₁₅ are as defined in claim 1, carboxyl, straight-chained or branched C₁₋₃alkyl having a protected amino; or a hydrate or pharmaceutically acceptable salt thereof.

29. (Previously Presented) A compound of Formula (5):



wherein:


Cy, R_6 , R_8 , R_9 , R_{20} , R_{10} , R_{12} , R_{13} , X and Y are as defined in claim 1;

R₇" is hydrogen, straight-chained or branched C₁₋₃alkyl optionally having at least one optionally protected

substituent, amino optionally having at least one optionally protected substituent or optionally protected hydroxy; and

R_{11}' is hydrogen, straight-chained or branched C_{1-3} alkyl optionally having at least one protected substituent, -CO-N(R_{14}) R_{15} wherein R_{14} and R_{15} are as defined in claim 1, carboxyl or a hydrate or pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



wherein:

R_8 is hydrogen, optionally-substituted straight-chained or branched C_{1-3} alkyl, optionally substituted amino, or hydroxy;


R_9 , is optionally-substituted straight-chained or branched C_{1-6} alkyl, optionally substituted straight-chained or branched C_{2-6} alkenyl, optionally substituted straight-chained or branched C_{2-6} alkynyl, C_{3-7} cycloalkyl or optionally substituted phenyl;

R_{20} is hydrogen or straight-chained or branched C_{1-3} alkyl; or R_9 and R_{20} may together form C_{3-7} cycloalkyl;

R_{10} is hydrogen or straight-chain or branched C_{1-3} alkyl;

R_{12} is hydroxy or OR_{16} ;

R_{13} is hydrogen, straight-chained or branched C_{1-6} alkyl, straight-chained or branched C_{2-6} alkenyl, straight-chained or branched C_{2-6} alkynyl or a group of Formula (3)



Wherein R_{17} is hydrogen or methyl;

R_{18} and R_{19} together form cycloalkenyl or C_{3-7} cycloalkenyl; and

Y is carbonyl or methylene;

P_1 is hydrogen or a protecting group of amine; and

R_{11} is hydrogen, optionally substituted straight-chained or branched C_{1-3} alkyl, ~~$-CO-N(R_{14})R_{15}$ wherein R_{14} and R_{15} , which may be the same or different, are hydrogen, optionally substituted straight chained or branched C_{1-4} alkyl, C_{3-7} cycloalkyl, straight chained or branched C_{1-4} alkoxy, straight chained or branched C_{1-4} alkylsulfonyl or a heterocyclic ring, carboxyl, straight-chained or branched C_{1-3} alkyl having protected amino or an optionally substituted heterocyclic ring, or $-CO-N(R_{14})R_{15}$ wherein R_{14} and R_{15} , which may be the same or different, are hydrogen, optionally substituted straight-chained or branched C_{1-4} alkyl, C_{3-7} cycloalkyl, straight-chained or branched C_{1-4} alkoxy, straight-chained or branched C_{1-4} alkylsulfonyl or a heterocyclic ring, carboxyl, straight-chained or branched C_{1-3} alkyl having protected amino or an optionally substituted heterocyclic ring;~~

or a hydrate or pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)